Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
The company recently incorporated a new entity in the name of Lupin Digital Health Limited
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
7.94 crore doses were made available to the states in May 2021
Adjusted PAT declined 18.8% YoY
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Subscribe To Our Newsletter & Stay Updated
